ABSTRACT
Introduction: The COVID-19 pandemic has increased the burden on patients living with kidney disease. The higher lethality in this population is associated with an increase in 7 to 18-fold mortality compared to patients with chronic kidney disease who were not infected with the virus. This increased toll on patients with kidney disease urges that further studies be performed to understand the extent of the vulnerability of this population. Method(s): Retrospective cohort study. Patients with previous diagnoses of chronic kidney disease ( CKD) hospitalized with acute respiratory failure with a confirmed COVID-19 diagnosis from January to June 2021 were included. Anonymized data was obtained from the DATASUS public database. Missing data were excluded. Collected data included patients' demographics, clinical characteristics, and outcomes. Patients were stratified on the presence of other comorbidities. P-values < 0.05 were considered significant. Statistical analysis was performed using Microsoft Excel, SPSS IBM e Epi Info 7. Result(s): A total of 18,877 patients were included in the analysis. The majority (59,3 %) were male, and the mean age was 64,5 +/-15,4 years. The most common symptoms or signs in this population were dyspnea (72,5 %) followed by cough (60,9%) and low peripheral O2 saturation(71,0%). Regarding the comorbidities associated with chronic kidney disease, the most prevalent were Cardiovascular disease (55,9%), Diabetes mellitus (42,7%), and Obesity (11%). The presence of each individual comorbidity associated with CKD was noted to increase the risk of death for these patients (Table 1). [Formula presented] 95% C.I.:95 % Confidence Interval Conclusion(s): Cardiovascular disease, diabetes mellitus, and obesity associated with chronic kidney disease significantly increase the risk of poor outcomes in patients hospitalized with acute respiratory failure due to COVID-19. This increased risk should be considered when managing these patients. Furthermore, the interactions between the types of comorbidities must also be worthy of attention due to their risk differences. The simple quantification of the number of comorbidities of each patient or the presence or absence should be replaced and individualized on a patient-by-patient basis. No conflict of interestCopyright © 2023